- Pfizer pays $1.72 annually per share, giving PFE dividends a forward yield of 6.13% at $28.07.
- A negative reported payout ratio reflects largely noncash impairment charges, making cash flow and debt reduction more relevant dividend measures.
- Pipeline execution and product-exclusivity losses around 2028 remain central to the outlook for Pfizer dividends.
Dividend snapshot
At $28.07 per share, Pfizer pays a quarterly dividend of $0.43, or $1.72 annually, producing a forward yield of 6.13%. That is above its 5.82% five-year average yield and ahead of most large pharmaceutical peers.
The payment is unchanged from the prior quarter. Pfizer’s five-year dividend growth rate is 2.36%, making PFE dividends primarily a high-current-income proposition rather than a fast dividend-growth investment.
A $10,000 position at today’s price would buy roughly 356 shares and generate about $612 in annual dividends before taxes, assuming the current payment is maintained.
Cash flow offers a clearer payout view
Reported earnings make Pfizer dividend coverage appear weak, but headline GAAP results were affected after a -988.31% payout ratio was driven by $4.3 billion in largely noncash impairment charges tied to certain assets.
The charges do not make the dividend risk-free. Operating cash flow, free cash flow after research spending, debt repayment needs, and adjusted earnings are more useful measures than a one-time accounting loss.
Pfizer’s cash flow per share is listed at $2.35, above its $1.72 annualized dividend. Still, leverage of roughly 2.7 times and upcoming product exclusivity losses leave less room for operational disappointments.
Guidance and pipeline underpin PFE dividends
Near-term operations have improved, with management lifting 2026 revenue guidance to $60.5 billion–$62.5 billion while retaining adjusted EPS guidance of $2.80 to $3.00.
The longer-term challenge is replacing sales lost to generic and biosimilar competition, especially around 2028. Pfizer expects a meaningful 2026 headwind, while declining COVID-product revenue remains a drag.
Investors should watch oncology drug Padcev, Vyndamax, acquired medicines, and obesity candidate development. Clinical or regulatory progress could strengthen future cash generation, while setbacks could pressure the share price and confidence in dividend coverage.
High income with limited room for errors
Pfizer trades near the top of its 52-week range of $23.58 to $28.75. Its trailing P/E of 36.9 is distorted by weak GAAP earnings, while recent coverage cites estimates near nine times forward earnings.
A bullish case points to a $32.72 12-month target, implying potential capital appreciation alongside dividends. A longer-range mid-case estimate of about $32 by 2032 suggests income and reinvestment may drive much of the expected return.
Pfizer remains suited to measured income exposure, but its 6%-plus yield is not a guarantee. Investors should monitor free cash flow, debt reduction, pipeline milestones, and 2028 patent-expiration risks as they assess the durability of PFE dividends.
